News | June 11, 2013

Axxess Self-Expanding Bifurcation DES Safe, Effective up to Five Years

June 11, 2013 — New long-term data from the DIVERGE clinical study, presented at EuroPCR 2013 by Principal Investigator Dr. Stefan Verheye, Antwerp Cardiovascular Centre, ZNA Middelheim Hospital, Belgium, has shown that the use of the Axxess drug-eluting stent (DES) for the treatment of complex coronary bifurcation lesions resulted in low levels of both MACE and VLST over a five-year period. Axxess is now the only dedicated bifurcation stent with a substantial body of supporting data out to five years.

DIVERGE is a prospective, single-arm, multi-center study of 302 patients with de novo bifurcation lesions across 14 sites in Europe, Australia and New Zealand. It is the largest study conducted to date with a DES specifically designed for treating coronary bifurcation lesions. Following implantation of Axxess in the main branch, the side branch treatments were left at the operators’ discretion. Additional conventional sirolimus-eluting stents (SES) were placed in 21.7 percent of the distal parent and/or side branch vessels. In 64.7 percent of the cases both branches were treated with an additional SES.

At five years post-procedure, 96.3 percent of patients originally enrolled in the study (291) were available for follow-up. The cumulative rate of MACE (a composite of death, MI and ischemia-driven TLR) was 21.3 percent. The occurrences of the individual components were 6.5 percent for death, 8.6 percent for myocardial infarction and 12.4 percent for ischemia-driven TLR.

Only five cases (1.7 percent) of very late definite stent thrombosis (VLST) were reported, all of which involved at least one SES. None of these very rare VLST events resulted in the death of a patient.

"These long-term results from DIVERGE are important because of the frequent presentation of bifurcation lesions in our daily clinical practice," commented Verheye. "These types of lesions are associated with higher complication and restenosis rates compared to conventional lesions. Axxess is now the only dedicated bifurcation stent with this level of supporting data out to five years."

Axxess is a self-expanding dedicated bifurcation stent, which releases Biolimus A9 [BA9], an anti-restenotic drug designed by Biosensors specifically for use with stents, from an abluminal biodegradable polymer coating. Axxess incorporates a conical-shaped self-expanding nitinol (nickel/titanium) stent platform, specifically designed to conform to the shape of the bifurcation anatomy. This has been tailored to reconstruct the bifurcation without creating a false carina (the ridge where the two vessels join), lowering the risk of uncovered struts at the flow divider.

Biosensors received CE mark approval for Axxess in April 2011, supported by the positive nine-month results from the DIVERGE trial, which were published in the Journal of the American College of Cardiology (JACC) in March 2009. These demonstrated a very low in-stent restenosis rate of 6.4 percent in the overall bifurcation, and MACE rate of 7.6 percent, in patients treated with Axxess.

Axxess is currently available in many major markets worldwide (excluding the USA).

For more information:

Related Content

Pregnancy-Related Heart Failure Strikes Black Women Twice as Often as Other Races
News | Womens Healthcare| October 19, 2017
African American women were found to be twice as likely to be diagnosed with peripartum cardiomyopathy as compared to...
MRI May Predict Neurological Outcomes for Cardiac Arrest Survivors
News | Sudden Cardiac Arrest| October 18, 2017
Magnetic resonance imaging (MRI)-based measurements of the functional connections in the brain can help predict long-...
Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals| October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
First Patient Enrolled in U.S. Arm of ALIVE Pivotal Heart Failure Trial
News | Heart Failure| October 17, 2017
October 17, 2017 — BioVentrix Inc. recently announced enrollment of the first patient in the U.S.
Low Mortality and Stroke Risks Displayed for Minimally Invasive Aortic Valve Replacements
News | Heart Valve Technology| October 11, 2017
An analysis of more than 1,000 minimally invasive aortic valve replacements and more than 400 additional associated...
New Evaluation Sends Low-Risk ER Chest Pain Patients Home Sooner
News | Cardiac Diagnostics| October 10, 2017
A new evaluation to determine whether emergency room patients with chest pain can go home and follow up with their...
News | Pharmaceuticals| October 04, 2017
October 4, 2017 — MyoKardia Inc.
Medtronic Announces Post-Market Study for CoreValve Evolut Pro System
News | Heart Valve Technology| October 02, 2017
Medtronic plc recently announced a new post-market clinical study to evaluate its CoreValve Evolut Pro valve in...
Abbott has pulled the Absorb Bioresorbable scaffold stent off the market.

The biggest cardiac technology story in September was Abbott pulled the Absorb Bioresorbable scaffold stent off the market because poor sales.

Feature | October 02, 2017
October 2, 2017 — Here is the list of the most popular articles and videos on the Diagnostic and Interventional Cardi
BioCardia Announces 12-Month Results from TRIDENT Trial of Stem Cell Delivery System
News | Stem Cell Therapies| September 26, 2017
BioCardia Inc. recently announced 12-month results from the Phase II TRIDENT clinical trial, conducted by the...
Overlay Init